MEDIA CENTER - 2010 & 2011

November 21, 2011
Biotech Finances, a French electronic magazine specializing in reporting global biotech financing news publishes article on APIM Therapeutics (Issue 527, November 21; see A copy of the article (in French) can be downloaded here.

November 10, 2011
APIM Therapeutics announced today conclusion of a third seed follow-up financing round led by Scandinavian investment companies Birk Venture and Ro Invest in syndication with Sarsia Seed, a seed stage investor that has already led two investment transactions in APIM Therapeutics. Financing will be used to further advance the preclinical development of APIM Therapeutics' anti-cancer lead compound in selected tumor indications including blood cancer and solid tumors. For more information, please visit the following web site link: 

March 21, 2011
APIM Therapeutics announced today conclusion of a second seed follow up financing round by Sarsia Seed, a Norwegian seed stage life science fund. Financing will be used to advance the preclinical investigation of APIM Therapeutics' lead compound in further cancer in vivo studies, predominantly in Myeloma and Acute Myeloid Leukemia. For more information, please visit:

May 27, 2010
APIM Therapeutics announced today that Sarsia Seed, a Norwegian seed stage life science fund, has invested NOK 3.5 million (€ 440.000) in APIM Therapeutics. The company, a spin-out from the Norwegian University of Science and Technology (NTNU), is developing novel peptide drugs which have the potential to improve clinical outcomes achieved with a large group of existing first line chemotherapeutics.

Visit Media Center 2017
Visit Media Center 2015 & 2016
Visit Media Center 2013 & 2014
Visit Media Center 2012

To learn more the APIM-motif, ATX-101 and PCNA, please see attached the publications (given as pdf files):

1. Gilljam KM et al, 2009. Identification of a novel, widespread, and functionally important PCNA-binding motif. J Cell Biol 186, pp645-654.

2. Müller R et al, 2013. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7).

3. Baglo Y et al, 2014. Enhanced efficacy of bleomycin in bladder cancer cells by photochemical internalization. Biomed Res Int. 2014;2014:921296.

4. Gederaas OA et al, 2014. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Transl Oncol. 2014 Dec;7(6):812-23.

5. Olaisen C et al, 2014. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling. Cell Signal. 2015 Jul;27(7):1478-87.

The following posters presented in TAT and AACR 2016 meetings provide latest efficacy data in bladder and breast cancer models as well as genomic and kinomic analysis conducted in these tumors:

6. Poster presented in the 14th International Congress on Targeted Anticancer Therapies.

7. Poster presented in the AACR Precision Medicine Series Conference: Targeting the Vulnerabilities of Cancer. 

For an excellent review discussing the druggability of PCNA and ATX-101:

8. Wang Shao-Chun, 2014. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014 Apr;35(4):178-186.



APIM Therapeutics AS is a spin-off from the Norwegian University of Science and Technology (NTNU).

Visit our About Us page to find out more.

About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see

About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit to find out more.

About Birk Venture
Birk Venture is a Scandinavian venture company exclusively focusing on innovative life science companies. Visit to find out more.

About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit to find out more.